As recent studies correlate tumor angiogenesis with PSMA staining and the ability to utilize molecular imaging to monitor PSMA-avid tumors and their response to therapy, targeting PSMA-expressing endothelial cells of brain tumors may prove to be therapeutically useful (14, 15). Here, FOLH1 is linked to neoplasm.